Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6912269 | 0.99 | CTSK (0.51) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL26459466 | 0.85 | ALDH1A1 (0.57) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL31047722 | 0.85 | KYNU (0.59) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL22783671 | 0.84 | PPARA (0.53) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL6051919 | 0.83 | CTSK (0.49) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL6912965 | 0.82 | CTSK (0.48) | CTSKALDH1A1ALOX15CTSSCTSL | |
| Phosphonic Acid SCHEMBL7620939 | 0.81 | ALDH1A1 (0.62) | CTSKALDH1A1ALOX15CTSSCTSL | |
| Phosphoric Acid SCHEMBL7625630 | 0.81 | CTSK (0.52) | CTSKALDH1A1ALOX15CTSSCTSL | |
| Alanine SCHEMBL28766518 | 0.80 | CTSK (0.56) | CTSKALDH1A1ALOX15CTSSCTSL | |
| SCHEMBL6140023 | 0.77 | ATM (0.61) | CTSKCTSSCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762174-B1 | BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE | DOVETAIL TECHNOLOGIES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6498150-B2 | USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS | DOVETAIL TECHNOLOGIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6451853-B1 | Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity | DOVETAIL TECHNOLOGIES, INC | 2002-09-17 | — | — | US | disclosed |
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES INC. | 2002-03-21 | — | — | US | disclosed |
| US-6007819-A | Methods of inducing immunity using low molecular weight immune stimulants | DOVETAIL TECHNOLOGIES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999042099-A1 | LOW MOLECULAR WEIGHT COMPOUNDS ADMINISTERED TOGETHER WITH ANTI-CANCER AGENTS TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS THEREOF | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1997014306-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-4218404-A | HYPOGLYCEMIC AGENTS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | ACP1, CD14, HPGDS | CTSK 1049/4885ALDH1A1 4086/4885ALOX15 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.